Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.76 |
| ▸ | HTR1A | P08908 | 9/20 | 0.73 |
| ▸ | DRD2 | P14416 | 6/20 | 0.73 |
| ▸ | HTR2A | P28223 | 5/20 | 0.73 |
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
| ▸ | DRD3 | P35462 | 4/20 | 0.72 |
| ▸ | DRD5 | P21918 | 3/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836050 | 0.98 | HTR7 (0.72) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL9369051 | 0.86 | DRD2 (0.63) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL10517807 | 0.84 | DRD2 (0.64) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL21802146 | 0.84 | HTR1A (0.74) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL11630613 | 0.84 | HTR7 (0.73) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL11817633 | 0.84 | HTR7 (0.62) | HTR7HTR1ADRD2HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL10518350 | 0.84 | DRD2 (0.63) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL11465528 | 0.84 | SIGMAR1 (0.76) | HTR7HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL6865196 | 0.83 | HTR7 (0.87) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL10782032 | 0.83 | HTR7 (0.80) | HTR7HTR1ADRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | DRD3, DRD2, PRLHR | HTR7 144/4885HTR1A 112/4885DRD2 2/4885 |
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | DRD3, DRD2, PRLHR | HTR7 130/4885HTR1A 125/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.